Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

Asan Medical Center

Status and phase: Active, not recruiting; Phase 4

Conditions: Acute Kidney Injury; Liver Diseases

Treatments: Drug: Dexmedetomidine; Drug: Normal saline

Study type: Interventional

Funder types: Other

Identifiers

NCT03522688

DEX-LT

Details and patient eligibility

About

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Full description

Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of incidence between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one of the most important independent risk factors and recent reports have indicated that IRI is associated with an inflammatory cascade. Dexmedetomidine which is a highly selective agonist of α2-adrenergic receptors has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Enrollment: 214 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• living liver transplantation recipients

Exclusion criteria

• preoperative renal dysfunction
• dual living donor liver transplantation
• severe cerebral artery disease
• severe cardio-pulmonary disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

214 participants in 2 patient groups, including a placebo group

control group

Placebo Comparator group

Description:

The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour

Treatment:

Drug: Normal saline

treatment group

Active Comparator group

Description:

The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour

Treatment:

Drug: Dexmedetomidine